Despite overall improvements in outcomes of patients with diffuse large B cell lymphoma (DLBCL), B30-40% of patients develop relapsed or refractory disease. For patients with chemo refractory disease, or recurrent disease following autologous hematopoietic SCT (auto-HCT), the prognosis is poor, with no consensus on the optimal therapy. Currently, owing to the graft vs lymphoma effect, hematopoietic allogeneic hematopoietic cell transplantation (allo-HCT) is the only potentially curative option for such patients. In addition, many patients who are considered today for auto-HCT actually have a low likelihood of benefit. For example, a patient with prior rituximab exposure who relapses within 1 year of diagnosis and has a second-line age-adjusted International Prognosis Index of 2 or 3 at relapse has a o25% chance of being cured by auto-HCT. It is possible that such patients may be better served with an allo-HCT. Unfortunately, in many cases, allo-HCT applicability is limited by patient age, comorbidities, performance status and treatment-related toxicities. Recent attempts to improve the efficacy of auto-HCT, such as incorporating radio-immunotherapy into the conditioning regimen, have not resulted in improved outcomes. However, incorporation of novel agents such as antiprogrammed death-1 antibodies as maintenance therapy after auto-HCT show promise. Allo-HCT in relapsed/refractory DLBCL patients can result in a 30-40% PFS rate at 3 years, in part due to a graft vs DLBCL effect. While reduced-intensity/nonmyeloablative conditioning is increasingly being used, certain patients may benefit from myeloablative conditioning. We present an algorithm intended to discriminate which relapsed and refractory DLBCL patients are most likely to benefit from auto-HCT vs allo-HCT. New approaches, using novel agents that target the molecular heterogeneity in DLBCL, will be an essential component of moving the field forward. Lastly, we propose a prospective registry-based study as the only feasible mechanism to define the optimal position of allo-HCT in the overall treatment strategy for DLBCL. It is hoped that this review will promote the development of prospective multicenter efforts to determine whether such patients do, in fact, benefit from earlier and/or more effective implementation of allo-HCT.
INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) accounts for B30% of nonHodgkin lymphoma cases diagnosed in the United States annually. Following the incorporation of rituximab into treatment regimens, B60% of DLBCL cases are now cured with frontline therapy. For patients with relapsed or refractory DLBCL, particularly after failure of autologous hematopoietic cell transplantation (auto-HCT), allogeneic HCT offers the benefits of a tumor-free graft and the potential for a graft vs lymphoma (GVL) effect. Allo-HCT can be a curative therapy, for patients with relapsed or refractory DLBCL following auto-HCT and even in some cases for those with chemorefractory disease. [1] [2] [3] [4] [5] [6] [7] [8] Unfortunately, many patients who relapse or progress after auto-HCT never achieve sufficient disease control to become a suitable candidate for allo-HCT. In addition, non-relapse mortality (NRM) remains problematic for allo-HCT in this setting. Nonetheless, for some patients with a low chance of success with auto-HCT, allo-HCT may represent a superior therapeutic option. In order to more effectively employ allo-HCT for DLBCL, it is essential to identify patients for whom allo-HCT may be superior to auto-HCT and/or develop strategies that allow allo-HCT to be implemented more frequently or more effectively. In this article we review the existing literature regarding outcomes of allo-HCT for DLBCL, including evidence in support of a graft vs DLBCL effect. We also discuss approaches to reduce NRM, as well as an algorithm intended effectively to identify relapsed and refractory DLBCL patients unlikely to benefit from auto-HCT, for whom allo-HCT would be a reasonable alternative.
CURRENT STANDARD OF CARE FOR RELAPSED AND REFRACTORY DLBCL
The PARMA study originally demonstrated improved EFS and OS in favor of auto-HCT vs conventional salvage therapy alone for patients with relapsed, but chemotherapy-responsive, aggressive non-Hodgkin lymphoma. 9 With auto-HCT, a 5-year EFS of 46% and 5-year OS of 53% was seen. This study established auto-HCT as a standard of care for transplant-eligible patients who have relapsed, chemosensitive DLBCL. In clinical practice, the results have largely been extrapolated to include DLBCL patients with primary induction failure who have chemosensitive disease. However, although the PARMA study was a step forward, the current standard of care for patients with relapsed and refractory DLBCL leaves much to be desired. Although nearly 50% of patients in the PARMA study were event-free at 5 years, this trial only focused on relapsed patients, and only reported on patients who actually underwent transplantation. More recently, the CORAL study provided important information regarding outcomes of patients with relapsed and refractory DLBCL in the rituximab era. In this study, patients with relapsed and refractory DLBCL were enrolled with the intention to perform an auto-HCT. Disappointingly, only about 50% of such patients actually underwent auto-HCT. 10 In addition, in considering the entire group of patients enrolled, only 31% were event-free and only 50% alive at 3 years. Other important information from the CORAL study was the identification of a very poor risk group which has a small chance of benefitting from traditional auto-HCT. Specifically, patients who relapse/progress within 1 year of diagnosis and/or have a high second-line aaIPI (age-adjusted International Prognostic Index) have a very low chance of achieving longterm remission with auto-HCT (o25% when analyzed with the intention to treat).
There is therefore an urgent need to improve the therapy for patients with relapsed and refractory DLBCL. Several approaches could be taken in this regard. They include (1) modification of the salvage therapy regimen, (2) alteration of the auto-HCT-conditioning regimen, (3) post-transplant consolidation or maintenance therapy, (4) introduction of new or novel agents and (5) a more extensive or effective use of allo-HCT, or some combination of them. Several such attempts have been made or are currently under evaluation.
Modification of salvage therapy
The first randomization of the CORAL study showed no benefit of one salvage regimen (R-ICE; rituximab, ifosfamide, carboplatin and etoposide) over another (R-DHAP; rituximab, cytarabine and cisplatin). 10 The 3-year PFS was 37% overall (31% for R-ICE and 42% for R-DHAP, P ¼ 0.4); the rate of grades 3 and 4 hematologic and non-hematologic toxicities were higher in the R-DHAP arm, in particular thrombocytopenia and renal insufficiency. Of note, in subgroup analyses, patients with a germinal center B cell immunophenotype at the time of diagnosis had an improved PFS with R-DHAP (P ¼ 0.01), although OS did not quite reach statistical significance (P ¼ 0.08). With R-ICE, there was no difference in PFS according to the cell of origin. 11 In a non-randomized trial of patients with relapsed and refractory DLBCL, bortezomib plus dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) showed a significantly improved response rate (83% vs 13%, Po0.001) and median OS (10.8 vs 3.2 months, P ¼ 0.003) in non-germinal center B cell relative to germinal center B cell DLBCL. 12 These results suggest that specific salvage regimens may be more effective, depending on the molecular subtype. However, application of these observations to routine clinical practice would require prospective confirmatory studies.
Alteration of auto-HCT-conditioning regimen The most commonly utilized conditioning regimen for auto-HCT in DLBCL patients remains BEAM (carmustine (BCNU), etoposide, cytarabine (araC) and melphalan). Other conditioning regimens have been explored, such as Bu-Cy-E (busulfan, cyclophosphamide and etoposide), with no obvious benefit over BEAM. 13, 14 The addition of radio-immunotherapy to traditional BEAM conditioning has also been attempted in hopes of improving disease control without compromising tolerability. A recent randomized trial conducted by the Bone Marrow Transplantation Clinical Trials Network (BMT CTN 0401) showed no benefit of adding 131-Iodine tositumomab to standard BEAM, compared with BEAM plus rituximab. 15 Other groups are also investigating the addition of radio-immunotherapy agents to the conditioning regimen for auto-HCT. Unfortunately, these studies have either been nonrandomized, or suffered from very small patient numbers, limiting their interpretation. [16] [17] [18] Given the negative result from the BMT CTN 0401 trial, it seems unlikely that simply adding a radio-immunotherapeutic agent to the conditioning regimen will lead to a new standard of care.
Post-auto-HCT consolidation or maintenance The second randomization of the CORAL trial showed no benefit to post-transplant maintenance rituximab in the entire cohort, although a subset analysis revealed a benefit in female patients. 19 This finding likely is a reflection of less rapid rituximab clearance in women, which in turn leads to higher blood concentrations of rituximab. This observation could suggest a benefit of rituximab post auto-HCT in females (and possibly in males using higher than standard doses of rituximab), but this question remains unsettled. Advances in our understanding of tumor biology have led to the development of novel targeted therapies. For example, programmed death 1 (PD-1) is a T cell coreceptor that binds to the ligand B7 to maintain an immunosuppressive tumor microenvironment. Blocking this interaction may improve antitumor effector cell function. A recent non-randomized study used the anti-programmed death-1 Ab CT-011, following auto-HCT in relapsed and refractory DLBCL patients. The investigators reported an 18-month PFS of 69%, which compared favorably with historical controls. 20 Although promising, this result has not been confirmed in a prospective randomized trial. Therefore, despite these efforts, none of the first three approaches has yet to become standard practice.
New and novel agents Several new classes of agent are emerging as potential therapies for non-Hodgkin lymphoma, including immunomodulatory agents, mammalian target of rapamycin inhibitors, kinase inhibitors and Ab/toxin conjugates. In some cases, dramatic responses have been observed; however, in general these agents have shown modest activity in relapsed and refractory DLBCL, with overall response rates ranging from 11 to 47%, CR rates from 1 to 16% and median durations of remission generally in the 2-6 months range (Table 1) . [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] For many of these agents, studying specific subtypes of DLBCL (for example, the activated B cell subtype), or cases in which the target of the agent is known to be present, will likely prove to be more effective than simply enrolling all DLBCL cases. Therefore, some subtypes of DLBCL may ultimately prove to be amenable to maintenance therapy post transplant. One such approach would be to use an agent such as lenalidomide or ibrutinib for patients with the activated B cell-type DLBCL, as these agents are beneficial mainly in this subgroup. However, because of the molecular heterogeneity of DLBCL, it is unlikely that single 'targeted' therapy will dramatically alter the natural history of relapsed and refractory DLBCL. This leads us seriously to consider a more extensive and/or effective use of allo-HCT in DLBCL.
RETROSPECTIVE COMPARISONS OF ALLO-HCT AND AUTO-HCT
Comparative studies of auto-HCT vs allo-HCT have reported either no significant difference in survival between the two transplant modalities, 36 or an inferior survival in the allo-HCT cohort. 7 As seen with other lymphoma subtypes, an increase in NRM after allo-HCT and a suggestion of a lower relapse rate after allo-HCT has been observed. However, most relapses occur early in the posttransplant period, and any potential benefit in terms of reduced relapse after allo-HCT appears offset by higher NRM in the first 12 Allo-HCT for DLBCL E Klyuchnikov et al months. Allo-HCT clearly carries a higher rate of NRM (20-45% at 1-5 years), [1] [2] [3] [4] [5] 7, 8 and this risk increases with a higher intensity of the conditioning regimen, increasing age and declining performance status (see Table 2 ). As a significantly greater proportion of high-risk patients undergo allo-HCT, it is encouraging that the rate of relapse or progression observed after allo-HCT (25-41% at 3-5 years) has been similar to that in patients undergoing auto-HCT (30-40% at 3-5 years). [1] [2] [3] [4] [5] 7, 8, 15, 37, 38 Nevertheless, even though the relapse rates after allo-HCT may be lower than expected (given the high-risk nature of patients undergoing allo-HCT), methodologically, such retrospective comparisons are seriously hampered by selection bias, as patients selected for allo-HCT generally have significantly different characteristics compared with those selected for auto-HCT.
ARE THERE PATIENTS FOR WHOM ALLO-HCT SHOULD BE CHOSEN INSTEAD OF AUTO-HCT?
Despite the advantages of a graft vs DLBCL effect and a tumor-free graft offered by allo-HCT, the higher NRM of allo-HCT has largely limited its application to a third-line approach for the small subset of patients who have failed a previous auto-HCT and remain fit enough to undergo a second HCT procedure. Unfortunately, in practice, only about 19% of patients who relapse or progress after auto-HCT ultimately undergo allo-HCT. 8 Given the low anticipated chance for success with auto-HCT in many cases, such as those with rapid relapse and/or high second-line aaIPI after first-line rituximabcontaining therapy, the benefits of allo-HCT compared with auto-HCT may outweigh the risks for some of these high-risk patients. This could potentially make allo-HCT the preferred second-line approach in some cases. Conclusively proving this hypothesis would require a prospective randomized clinical trial. To date, neither has such a trial been completed, nor is one likely to be undertaken. As a result, there is no consensus on how best to identify patients who would be better served by allo-HCT (as opposed to auto-HCT) for second-line therapy. Given that a randomized clinical trial is unlikely to occur, how do we go about clarifying the role, if any, of allo-HCT in DLBCL?
EVIDENCE FOR A GRAFT VS DLBCL EFFECT
In general, a clinically relevant GVL effect has been defined as regression of lymphoma documented after withdrawal of immunosuppression or after DLI. 39 Additional evidence in support of a GVL effect would consist of lower relapse rates in recipients of allografts compared with those undergoing auto-HCT, and/or decreased relapse rates in patients who develop chronic GVHD (a surrogate for GVL). There are well-documented GVL effects for certain lymphoma subtypes such as follicular and mantle cell lymphoma. 40, 41 Whereas the evidence is less robust, there are data suggesting such an effect in DLBCL as well.
There are reports of clinical responses in DLBCL following withdrawal of immunosuppression or DLI. Bishop et al. 42 analyzed 18 relapsed/refractory DLBCL patients who underwent allo-HCT following a RIC regimen consisting of fludarabine and CY. Eleven of the fifteen patients who were not in CR on day þ 100 post transplant or developed relapse were initially treated by withdrawal of immunosuppression or DLI alone, whereas four patients received DLI with prior chemotherapy. Response (even to withdrawal of immunosuppression alone) was seen in 9 of the 15 patients. Five responders developed GVHD. Six of the nine responders were alive in remission after a median follow-up of 68 months. Thomson et al.
2 also presented evidence for a GVL effect in DLBCL, with 5 of the 12 patients showing responses (including some durable remissions) following DLI.
As described above, due to selection bias in DLBCL patients selected for allo-HCT vs auto-HCT, it is not clear from retrospective comparisons whether relapse rates after allo-HCT are lower than those observed after auto-HCT. However, Sirvent et al. demonstrated a trend towards a decreased relapse incidence in DLBCL patients who developed chronic GVHD (relative risk of 0.47, with P ¼ 0.09). In addition, the fact that a proportion of relapsed and refractory DLBCL patients (even those with chemoresistant disease) 6 can achieve long-term remission after non-myeloablative (NMAC) and reduced-intensity (RIC)-conditioning allo-HCT suggests that a clinically meaningful GVL effect exists and benefits some patients with DLBCL. 1, [43] [44] [45] [46] [47] Thus, there is evidence to support a GVL effect in DLBCL. Differences in the intrinsic antigen-presenting ability of DLBCL cells as compared with indolent lymphomas may provide an explanation for a potentially weaker GVL effect in DLBCL. 48 In addition, the more aggressive growth kinetics of DLBCL (compared with follicular and mantle cell lymphoma) may outpace an effective GVL response in many cases. However, there are strategies that could be employed to enhance the GVL response. These maneuvers include early withdrawal of immunosuppression, use of ex vivo activated/expanded T-or NK cells, 49, 50 or enhancement of antitumor effector T cell function by Allo-HCT for DLBCL E Klyuchnikov et al modulation of the lymphoma microenvironment. 51 Treatment with a proteosome inhibitor following allo-HCT may also be beneficial in this regard, as NF-kB is upregulated in some cases of DLBCL and also because bortezomib can reduce the risk of GVHD. 52 
IMPACT OF PRETRANSPLANT CONDITIONING
In a recent CIBMTR report, we analyzed the outcomes of 396 adults who received allo-HCT for DLBCL primarily from unrelated donors (67%), following myeloablative conditioning (MAC; n ¼ 165), RIC (n ¼ 143) or NMAC (n ¼ 88) between 2000 and 2009. RIC and NMAC recipients were older, more likely to have received prior auto-HCT, prior irradiation and more prior chemotherapy regimens than MAC recipients. The NRM rate at 5 years was significantly higher in MAC recipients than in the RIC and NMAC groups (56% vs 47% vs 36%; P ¼ 0.007). Lymphoma relapse/progression at 5 years was significantly lower in the MAC group than in the RIC and NMAC (26% vs 38% vs 40%; P ¼ 0.031) groups, but the respective 5-year PFS (18, 15 and 25%) and OS rates (18, 20 and 26%) did not differ significantly. 5 These results were in close agreement with a previous study from van Kampen et al., 4 who reported on the EBMT experience in 101 patients with relapsed/refractory DLBCL, receiving either MAC (TBI/CY or BU/CY) or RIC allo-HCT (mostly fludarabine-based) following a prior auto-HCT. The 3-year NRM was 41% after MAC allo-HCT, compared with 20% after RIC allo-HCT. The 3-year PFS and OS were similar for MAC and RIC patients at 42 and 52%, respectively. Thus, MAC has been associated with increased NRM and (in some reports) decreased relapse incidence, compared with RIC (Table 2) . Differences in DFS and OS were also seen in relation to the time from auto-HCT until relapse, with the laterelapsing patients faring substantially better. In the recently published study of the GITMO, which included 165 patients with relapse or progression of DLBCL after prior auto-HCT, patients received allo-HCT using RIC or MAC regimens. The 5-year OS and PFS were 39 and 31%, respectively, for the whole cohort. Multivariate analysis indicated that the only factor affecting OS was the disease status at allo-HCT, and PFS was influenced by disease status at allo-HCT and donor type, with the use of sibling donors being associated with improved PFS. 8 Although OS was not statistically worse with MAC in this study (OS 37% with MAC and 48% with NMAC, P-value NS), this was a smaller study than the CIBMTR study, and therefore had less power to detect a significant survival difference.
Two recent studies have evaluated the use of RIC regimens in DLBCL patients. Sirvent et al. 3 reported on 68 relapsed/refractory DLBCL patients who underwent allo-HCT mostly after fludarabinebased RIC, preferentially from matched related donors. Most patients (78%) had a history of a previous auto-HCT. The authors observed a lower cumulative incidence of NRM (at 2 years, 23%); however, the relapse rate (at 2 years, 41%) and OS (2 years, 49%) were comparable to other studies (Table 2) . Rezvani et al. 1 evaluated the use of fludarabine/low-dose TBI allo-HCT in 32 DLBCL patients. The majority received PB grafts from matched related donor, and 75% had a history of a prior auto-HCT. The NRM at 3 years was 25%, and the 3-year OS was 45%, respectively. The relapse incidence at 3 years was 41%.
Therefore, the collective results of several, mostly retrospective, studies indicate an increased NRM and decreased relapse incidence after the use of MAC regimens. Although MAC allo-HCT seems to have no clear OS advantage over RIC, in general, for patients with relapsed and refractory DLBCL, for the subgroup of DLBCL patients who are young and fit, with high-risk disease, it is logical (although not yet proven) that MAC may afford better disease control vs RIC, without as much increase in NRM risk. For older DLBCL patients, those with comorbid conditions, or those with prior auto-HCT, RIC or NMAC appears to be the better option, (3) 41 (3) 45 (3) 35 (3) Thomson et al. (4) 33 (4) 47 (4) 48 (4) Sirvent et al. 23 (1) 41 (2) 49 (2) 44 (2) Lazarus et al. 45 (5) 33 (5) 22 (5) 22 (5) van Kampen et al. 30 (3) 52 (3) 42 (3) Rigacci et al. 39 (5) 31 (5) Bacher et al. 56 (5) 47 (5) 36 (5) 26 (5) 38 (5) 40 (5) 18 20 26 18 (5) 15 (5) 25 (5) Abbreviations: allo-HCT ¼ allogeneic cell transplantation; auto-HCT ¼ autologous hematopoietic cell transplantation; Eto Allo-HCT for DLBCL E Klyuchnikov et al particularly for patients in a CR prior to allo-HCT. For younger, fit patients with high-risk disease who achieve a CR prior to allo-HCT, RIC may also be preferred owing to a lower NRM than MAC, and reduced need for immediate antitumor effects compared with patients with active disease going into transplant.
HOW CAN WE MOVE FORWARD AND UTILIZE ALLO-HCT MORE EFFECTIVELY IN DLBCL?
Given the evidence for a GVL effect in DLBCL, combined with the disappointing outcomes for 'high-risk' patients with auto-HCT, we propose that a more extensive use of allo-HCT may translate to improved outcomes for patients with relapsed and refractory DLBCL. However, it will be important to define specific subgroups of patients who are most likely to tolerate, and also most likely to benefit from, allo-HCT over other available treatment options.
As a first step, we propose an algorithm for utilization of HCT in DLBCL (Figure 1 ). This algorithm aims to identify a subgroup of relapsed/refractory DLBCL patients for whom auto-HCT is unlikely to be of benefit, and for whom allo-HCT is likely to be tolerated. In addition, patients who have already failed an auto-HCT should remain candidates for allo-HCT.
To truly move the field forward, we feel that two parallel efforts need to be carried out. It is not the time to conduct a randomized controlled trial of allo-HCT for DLBCL. There are limited prospective data, and what little there is, is in heterogeneous groups, later in the disease course than we believe would be the ideal setting to evaluate allo-HCT. Instead, a multicenter prospective cohort (registry) study should be conducted. Participating centers could adopt a strategy of allo-HCT in patients for whom the data support a low likelihood of benefit from auto-HCT, as per our proposed algorithm. As all patients at any participating center are tracked, such patients could be flagged and an analysis would then be conducted after an adequate number of patients has been transplanted to allow meaningful comparisons. A priori sample size calculations and a statistical plan along with eligibility criteria would determine the specifics of accrual and analysis. As with all observational studies, the details of how the transplant is conducted would remain the purview of the transplant center. Intent to follow the algorithm, large numbers, comprehensive data and multivariate analysis would provide for a robust estimate of the benefit of allo-HCT in this patient population. Centers that do not participate in the prospective cohort study could provide an additional comparator group. Although not a randomized clinical trial, failure to show significant benefit for allo-HCT in such a study would seriously call into question whether this therapeutic strategy merits further investigation in the absence of transformational developments in allo-HCT. Concurrently, efforts need to continue to improve the clinical application of molecular subtyping of DLBCL, so that novel agents targeting specific pathways can be applied in patients most likely to benefit from these therapies. Ultimately, both efforts will hopefully converge, such that the optimal transplant procedure can be determined and paired with the optimal 'maintenance' therapy for a given patient.
CONCLUSIONS AND PERSPECTIVES
Despite improved outcomes with the incorporation of rituximab into frontline conventional therapy, B40% of patients with DLBCL still ultimately relapse or develop refractory disease. The PARMA trial sets a precedent as the first prospective randomized trial in relapsed DLBCL, showing a benefit to auto-HCT vs conventional second-line therapy. 9 As a result, auto-HCT is currently considered the standard of care for transplant-eligible patients whose DLBCL is chemosensitive. Whereas some of these patients achieve long- Chemosensitivity not required but patient should not be progressing on salvage therapy and should have a low/moderate disease burden.
z RIC if 460 yrs or prior auto-HCT. For others consider either MAC or RIC, based on age, KPS, HCT-CI and disease burden. aaIPI, Age-adjusted International Prognostic Index; Allo-HCT, allogeneic hematopoietic cell transplantation; Auto-HCT, autologous hematopoietic cell transplantation; HCT-CI, Hematopoietic Cell Transplantation Comorbidity Index; KPS, Karnofsky performance status; MAC, myeloablative conditioning; NRM, non-relapse mortality; RIC, reduced-intensity conditioning.
Allo-HCT for DLBCL E Klyuchnikov et al term remission with auto-HCT, many will progress despite auto-HCT. The introduction of rituximab has resulted in fewer relapsed and refractory DLBCL patients, but also has decreased the likelihood of cure for relapsed/refractory DLBCL patients with a standard auto-HCT. For such patients, therapeutic alternatives are desperately needed. To date, alterations in salvage therapy or auto-HCT-conditioning regimen or incorporation of maintenance therapy after auto-HCT have not improved the outcomes. Owing to a graft vs DLBCL effect, allo-HCT offers the chance for cure in a subset of relapsed and refractory DLBCL patients. However, in current practice, allo-HCT is utilized for only a small subset of DLBCL patients and typically is late in the disease course when the chance for benefit is low. An earlier and more effective implementation of allo-HCT, with incorporation of new and novel agents during or after transplant, and/or interventions designed to enhance the GVL effect hold promise. We believe that a prospective cohort study, rather than a cooperative group trial, would be the most effective mechanism to determine if allo-HCT, as currently practiced, should be pursued instead of auto-HCT for a defined high-risk subset of DLBCL patients. Although there are many new agents showing some degree of activity in DLBCL, most of these agents have response rates in the 20-40% range. Recent studies have identified significant molecular heterogeneity of DLBCL. 53 It will therefore ultimately be necessary to assay for several potential therapeutic targets in order to select the best regimen for an individual patient, ideally, in combination with either auto-HCT or allo-HCT, depending on the specific patient and disease characteristics. This would allow for 'individualized therapy' such that the proper 'targeted' agent can be matched to the appropriate tumor biology. Such an approach will require complex or novel trial designs, cooperation of multiple medical centers and biopharmaceutical companies, and creativity at the regulatory level-in essence, a transformation of clinical research from where it is today. Only by following such a path can clinical medicine match the strides being made in the laboratory understanding of tumor biology.
